Log In

 

Company Name : Takeda Pharmaceutical Company Limited

Saturday, February 3, 2018 7:43PM IST (2:13PM GMT)

(BW)(TAKEDA-PHARMACEUTICAL)

Takeda Reports 3rd Quarter FY2017 Results


Continued strong performance delivering double-digit earnings growth year-to-date; raising full-year guidance with Core Earnings margin expansion now projected at 300bps


Osaka, Japan

Takeda Pharmaceutical Company Limited (TOKYO:4502):

 

Underlying Revenue growth +6.7% led by Takeda's Growth Drivers

 
  • Underlying Revenue grew +6.7% year-to-date, with Takeda's Growth Drivers (Gastroenterology, Oncology, Neuroscience and Emerging Markets) posting strong underlying revenue growth of +14.5%.
    • Gastroenterology +23.7% fueled by market share growth of ENTYVIO® and TAKECAB®.
    • Oncology +13.8% driven by the expansion of NINLARO® and ADCETRIS®, and the addition of revenue from ICLUSIG® and ALUNBRIG®.
    • Neuroscience +26.4% led by robust growth of TRINTELLIX® in the U.S.
    • Emerging Markets +1.9% with strong performance in Russia and Brazil offsetting temporary declines in China and the Middle East.
  • Underlying Revenue performance was driven by double-digit growth in the U.S. (U.S. +17.0%, Japan +1.3%, Europe & Canada +4.9%).
  • Reported revenue grew +4.1%, with the positive contribution from Takeda's Growth Drivers and favorable currency impact (+3.4pp) more than offsetting the negative impact of divestitures (-5.9pp).

Double-digit EPS growth reflecting strong revenue growth and progress of Global Opex Initiative

 
  • Underlying Core Earnings grew +32.8%, reflecting strong revenue growth and margin step-up of 3.9pp (+2.3pp gross margin; +1.6pp from OPEX margin).
  • Reported operating profit was up +48.2%, driven mainly by Core Earnings growth. It also includes one-time gains of 136.9 billion yen, including the sale of shares held in Wako Pure Chemical Ltd., disposal of real estate, and the transfer of additional long-listed products to Teva Takeda Yakuhin Ltd.
  • Underlying Core EPS was up +25.8%, and reported EPS increased +45.5% to 309 yen per share.

Net leverage improved due to steady progress on cash flow

 
  • Year-to-date Operating Free Cash Flow increased +25.1% to 152.1 billion yen, and the disposal of non-core assets generated an additional 142.9 billion yen of cash.
  • Net Debt / EBITDA dropped to 1.9x from 2.7x in March 2017.

James Kehoe, Chief Financial Officer, commented:
"Our Growth Drivers continued to power ahead and, together with our cost management initiatives, led to double-digit earnings growth and significant margin expansion. We are updating our full year guidance to reflect higher Velcade sales, and we now project Core Earnings margin expansion of approximately 300bps. Takeda will continue to deliver value to patients and shareholders as we execute against our key mid-term priorities of growing the portfolio, rebuilding the pipeline, and boosting profitability."

 

Reported Results for Q3 YTD (April - December) FY2017

(billion yen)  

FY2016
Q3 YTD

 

FY2017
Q3 YTD

  % Growth vs Prior Year
      Reported   Underlying2
Revenue   1,315.8   1,369.6   +4.1%   +6.7%
Core Earnings1   228.3   292.7   +28.2%   +32.8%
Operating Profit   217.4   322.3   +48.2%   -
Net Profit3   165.7   240.9   +45.4%   -
EPS   212 yen   309 yen   +45.5%   +25.8%

1

  Core Earnings is calculated by deducting SG&A expenses and R&D expenses from reported Gross Profit. In addition, certain other items that are non-core in nature and significant in value may also be adjusted.

2

  Underlying growth compares two periods of financial results on a common basis, showing the ongoing performance of the business excluding the impact of foreign exchange and divestitures.

3

  Attributable to the owners of the company.
 

FY2017 Management Guidance: Raising full year underlying guidance to reflect higher Velcade sales;
now projecting Core Earnings growth in the "high twenties"

    Previous Guidance (growth %)
(Nov 1, 2017)
  Revised Guidance (growth %)
(Feb 1, 2018)
Underlying Revenue   Low single digit   Mid single digit
Underlying Core Earnings   High teen   High twenties
Underlying Core EPS   Mid teen   Mid twenties
Annual Dividend per Share   180 yen   180 yen
 

FY2017 Reported Forecast: Raising revenue & profit forecast to reflect Velcade upside;
EPS growth now at 36.9%. Forecast includes impacts from US Tax Legislation and Teva JV impairment

(billion yen)   Previous Forecast
(Nov 1, 2017)
 

Revised Forecast
(Feb 1, 2018)

  vs. FY2016
Revenue   1,720.0     1,745.0     +0.7%  
Core Earnings   267.5     289.5     +18.1%  
Operating Profit   200.0     218.7     +40.3%  
Net Profit   152.0     157.3     +36.9%  
EPS   195 yen     201 yen     +36.9%  
Exchange Rate (annual average)   1 US$=112 yen

1 euro=129 yen

  1 US$=112 yen

1 euro=130 yen

   
 

For more details on Takeda's FY2017 3rd quarter results and other financial information, please visit https://www.takeda.com/investors/reports/

 

About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and neuroscience therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. Innovative products, especially in oncology and gastroenterology, as well as Takeda’s presence in emerging markets, are currently fueling the growth of Takeda. Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda’s partners in health care in more than 70 countries.
For more information, visit https://www.takeda.com/newsroom/.

 

 

 

 


Click here for Media Contact Details
CONTACTS :

Investor Relations
Takeda Pharmaceutical Company Limited
Takashi Okubo, +81-(0)3-3278-2306
takeda.ir.contact@takeda.com
Media Relations
Takeda Pharmaceutical Company Limited
Kazumi Kobayashi, +81 (0)3-3278-2095
kazumi.kobayashi@takeda.com


More News from Takeda Pharmaceutical Company Limited

31/07/2018 6:15PM

Takeda Reports First Quarter FY2018 Results

Strong start on underlying revenue and profitability led by Growth Drivers and Opex discipline Reported operating profit and EPS impacted by large transactions in Q1 FY2017: 106.3 billion yen one-time gain on the ...

25/07/2018 6:22PM

Takeda Announces Phase 3 Trial of ALUNBRIG® (brigatinib) Met Primary Endpoint Demonstrating Superiority in Progression-Free Survival Versus Crizotinib in Patients with ALK+ Advanced NSCLC Who are ALK Inhibitor Naïve

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the global, randomized, Phase 3 ALTA-1L (ALK in Lung Cancer Trial of AP26113 in 1stLine) trial met its primary endpoint at the first pre-specified ...

19/07/2018 2:23PM

New Phase 3 Data Show Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Moderately to Severely Active Ulcerative Colitis

Takeda Pharmaceutical Company Limited [TSE:4502] (“Takeda”) today announced top-line results from the VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous (SC) ...

Similar News

17/08/2018 4:00PM

निवेशकों ने अबराज ग्रुप से अबराज ग्रोथ मार्केट्स हेल्‍थ फंड को अलग करने के लिए एलिक्‍सपार्टनर्स को नियुक्‍त किया

अबराज ग्रोथ मार्केट्स हेल्‍थ फंड (“एजीएचएफ” अथवा “द फंड”) में निवेशकों ने एजीएचएफ में अपनी मजबूत प्रतिबद्धता पर जोर दिया है। निवेशकों ने वैश्विक परामर्श कंपनी एलिक्‍सपार्टनर्स ...

No Image

17/08/2018 3:48PM Image

Century Pai Foundation Takes a Step Towards Helping Channahalli Residents Live a Healthier Life

Century Pai Foundation recently conducted free medical check-up camps for the villagers of Channahalli in the third quarter of its 15 check-up long CSR engagement with the community. The medical camp registered an ...